Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2019 | Managing CRS after anti-BCMA CAR-T for myeloma

He Huang • 17 May 2019
COMy 2019
Multiple Myeloma CAR-T Tocilizumab

He Huang, MD, PhD, of Zhejiang University School of Medicine, Zhejiang, China discusses how the majority of patients receiving BCMA CAR-T therapies suffer from cytokine release syndrome (CRS). Dr Huang also discusses different treatments including the anti-interleukin-6 antibodies. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from He Huang

3:09
An update on the experience with CAR T-cell therapy in China
He Huang • 16 Feb 2024
4:17
Novel CAR T-cell therapies for hematological malignancies: exploring new targets
He Huang • 16 Feb 2024
6:29
HSCT & CAR-T therapy during COVID-19: Chinese experience
He Huang • 2 Feb 2021
2:37
CAR-T cells for myeloma: experience from China
He Huang • 16 May 2019

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals